Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future res
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 2014 UBM Medica US announces that ... community for primary care clinicians offers a photo collection ... victims of a variety of summer scourges.  ... a host of medical menaces: poison ivy, tick-borne infections, ... the highlights covered on Consultantlive,s topic center that includes ...
(Date:7/21/2014)... 2014 By order of the U.S. Bankruptcy Court, ... of ophthalmic and optical equipment, designer eyeglass frames, and other ... American Optical Services LLC. Online bidding opens July ... succession, live auction style, on July 28 beginning at 10:30 ... be held July 25 th and 26 th ...
(Date:7/21/2014)... Israel , July 21, 2014 Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, announced today that it ... July 25, 2014 to discuss results for the period ... on current developments with respect to its clinical program ...
Breaking Medicine Technology:ConsultantLive Presents Special Coverage of Summer Scourges 2ConsultantLive Presents Special Coverage of Summer Scourges 3Auction Set For Assets Of National Optical Services Company 2Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2
... (NYSE Euronext Paris: COX) today announced that the ... with OA of the hip showed a highly,statistically ... of the trial. Naproxcinod 750 mg bid showed ... similar blood pressure profile,to placebo. Naproxcinod is the ...
... Nov. 21 Millions of Americans with moderate to severe ... new treatment option. Today, Johnson & Johnson Pharmaceutical Research ... Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief ... of age or older. , , ...
Cached Medicine Technology:Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 2Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 3Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 4Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 2FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 3FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 4FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 5FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain 6
(Date:7/22/2014)... CT (PRWEB) July 22, 2014 ... to meet new Department of Transportation regulations: all ... examiners for the US Department of Transportation (DOT). ... the road, the DOT enforces strict standards to ... to operate limousines, taxis, trucks, and other commercial ...
(Date:7/22/2014)... CA (PRWEB) July 22, 2014 ... provider of enterprise Time and Attendance / Workforce ... Iowa, a NOVAtime 3000 customer since 2007, has ... licensed version of NOVAtime’s state-of-the-art, web-based time and ... Services in Iowa (LSI) is a human services ...
(Date:7/22/2014)... Most people encounter the same two problems when trying to ... is a fast metabolism. These are hard problems to counteract on ... help fight these problems and to finally gain weight. , The ... who just can’t seem to eat more than a couple bites ... cause of this problem can vary. For some it can be ...
(Date:7/21/2014)... and kill cancer cells could boost the effectiveness of ... amputation, a new study reports. , Scientists at The ... a genetically engineered version of the virus used to ... virus alongside isolated limb perfusion chemotherapy given directly ... as an alternative to amputation was more effective ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 iFitDress.com, a ... for women, has announced its exclusive collection of 2014 ... launched a promotion for its brand new gowns. , ... in the current market. Its sales boomed in the ... elegant products, but also because of the amicable services ...
Breaking Medicine News(10 mins):Health News:PhysicianOne Urgent Care Physicians Become Certified Medical Examiners for DOT Physicals 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2
... birth control in all the schools of England in a ... ,There are currently 2,409 nurses who work in primary and ... a massive extension, reported the online edition of Daily Mail. ... funded to have at least one full-time qualified nurse working ...
... European Breast Cancer Conference (EBCC-5) have called that patients should ... in the field. Doctors and patient groups said that women ... like Herceptin that could help prolong their survival and well ... and radiation therapy are available to women in the United ...
... of Veterinary Medicine have established a national surveillance ... humans and animals using medical records of pets. ... of Epidemiology. Larry Glickman of the School of ... Hospital, a nationwide chain of veterinary hospitals to ...
... without any warning has become a health hazard today with ... per annum. Internal automatic defibrillators (IAD) have now come to ... these apparatus have brought many back from the brink of ... that approximately 1000 people die each year due to sudden ...
... crisis has its origin in HIV/AIDS, weak health systems and ... die from TB every year, 1.5 million are Africans. ... Research Foundation (AMREF) clinic in the Kenyan slum, revealed that ... infected with HIV. According to Nzioka, about two thirds of ...
... a study by the New England Research Institutes in collaboration ... much or too little// are at a greater risk of ... is based on studies done on over 1709 men, in ... over a period of 15 yrs. ,According to ...
Cached Medicine News:Health News:Pets As Disease Watchdogs 2Health News:Seconds Between Life And Death 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: